Cargando…

Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer

BACKGROUND: To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in terms of progression-free survival (PFS) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Jun, Otoyama, Yumi, Fujita, Ken-ichi, Goto, Kaku, Tojo, Masayuki, Katagiri, Atsushi, Nozawa, Hisako, Kubota, Yutaro, Takahashi, Takehiro, Ishida, Hiroo, Tsunoda, Takuya, Matsumoto, Natsumi, Ogawa, Keita, Nakagawa, Ryo, Muroyama, Ryosuke, Kato, Naoya, Yoshida, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019943/ https://www.ncbi.nlm.nih.gov/pubmed/35443621 http://dx.doi.org/10.1186/s12885-022-09512-5

Ejemplares similares

Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding
por: Arai, Jun, et al.
Publicado: (2020)

The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review
por: Arai, Jun, et al.
Publicado: (2022)

Associations of HLA‐C*01:02 and HLA‐B*46:01 with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer
por: Fujita, Ken‐ichi, et al.
Publicado: (2023)

Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma
por: Kumar, Vinod, et al.
Publicado: (2012)

Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA
por: Ohno, Motoko, et al.
Publicado: (2014)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
por: Nio, Yuta, et al.
Publicado: (2022)

The Characteristic Changes in Hepatitis B Virus X Region for Hepatocellular Carcinoma: A Comprehensive Analysis Based on Global Data
por: Li, Wenwen, et al.
Publicado: (2015)

Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
por: Lawson McLean, Aaron
Publicado: (2023)

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
por: Satoh, Etsuko, et al.
Publicado: (2018)

Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study
por: Goto, Kaku, et al.
Publicado: (2016)

A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review
por: Fuji, Takahiro, et al.
Publicado: (2022)

Transforming ground mica into high-performance biomimetic polymeric mica film
por: Pan, Xiao-Feng, et al.
Publicado: (2018)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
por: Zingoni, Alessandra, et al.
Publicado: (2018)

MICA*019 Allele and Soluble MICA as Biomarkers for Ankylosing Spondylitis in Taiwanese
por: Wang, Chin-Man, et al.
Publicado: (2021)

Identification of a Functional Variant in the MICA Promoter Which Regulates MICA Expression and Increases HCV-Related Hepatocellular Carcinoma Risk
por: Lo, Paulisally Hau Yi, et al.
Publicado: (2013)

New Uses for Mica
Publicado: (1869)

Possible origin of life between mica sheets: does life imitate mica?
por: Hansma, Helen Greenwood
Publicado: (2012)

MICA*049, not MICA*009, is associated with Behçet’s disease in a Chinese population
por: Zhu, Weifeng, et al.
Publicado: (2019)

Establishment of HLA class I and MICA/B null HEK-293T panel expressing single MICA alleles to detect anti-MICA antibodies
por: Jeon, Ji-Ho, et al.
Publicado: (2021)

Decreased expression of interferon‐stimulated genes in B cells of patients with chronic hepatitis C during interferon‐free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study
por: Arai, Jun, et al.
Publicado: (2020)

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
por: Abbona, Andrea, et al.
Publicado: (2023)

The Mica Myth in Darjeeling Water
por: Ray, Nishi Kanta
Publicado: (1934)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Neutrophilic dermatosis with necrobiotic changes as an unusual manifestation after the first shot of a COVID‐19 mRNA vaccine together with a high fever and liver injury
por: Iijima, Shigeruko, et al.
Publicado: (2022)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Thermal Behavior of Muscovite Sheet Mica
por: Ruthberg, Stanley
Publicado: (1963)

Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure
por: Fujita, Ken-ichi, et al.
Publicado: (2019)

Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Sasaki, Yasutsuna, et al.
Publicado: (2015)

Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch
por: Ming, Yingzi, et al.
Publicado: (2015)

The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA
por: Isernhagen, Antje, et al.
Publicado: (2015)

Association between MICA polymorphisms, s-MICA levels, and pancreatic cancer risk in a population-based case-control study
por: Onyeaghala, Guillaume, et al.
Publicado: (2019)

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
por: Secchiari, Florencia, et al.
Publicado: (2022)

Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye‐drops among rats, rabbits and monkeys
por: Horita, Shinya, et al.
Publicado: (2019)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma
por: Kojima, Ryuta, et al.
Publicado: (2023)

Mighty mica: synthetic clay remediates radium.
por: Frazer, Lance
Publicado: (2002)

Targeting MICA with therapeutic antibodies for the treatment of cancer
por: Bonnafous, Cécile, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nbtah4p0o3pd42011p3qh1scoo